Valuation: SENSORION

Market Cap 129M 147M 119M 110M 208M 14.05B 212M 1.42B 554M 6.89B 551M 540M 23.89B P/E 2026 *
-16.7x
P/E 2027 * -3.85x
Enterprise Value -3.32M -3.79M -3.06M -2.83M -5.37M -363M -5.47M -36.74M -14.3M -178M -14.23M -13.92M -616M EV / Sales 2026 *
-0.15x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2026-05-31
Director of Finance/CFO - 2024-06-25
Chief Tech/Sci/R&D Officer - 2023-12-10
Director TitleAgeSince
Director/Board Member - 2015-03-08
Director/Board Member 43 -
Chairman 61 2023-03-29
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.33%+417.51%+619.10% 40.49B
-2.29%+5.93%+25.27%+59.26% 34.35B
-2.13%+5.47%+25.45%-6.01% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.92% - - 16.58B
-2.62%+0.45%+66.82%+125.87% 15.6B
-2.17%+6.52%+102.15%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -1.05%+3.99%+81.87%+120.52% 27.39B
Weighted average by Cap. -1.00%+4.37%+93.71%+139.18%

Financials

2026 *2027 *
Net sales 21.86M 24.96M 20.17M 18.64M 35.36M 2.39B 36M 242M 94.11M 1.17B 93.66M 91.64M 4.06B 6.4M 7.3M 5.9M 5.45M 10.35M 698M 10.53M 70.77M 27.53M 343M 27.4M 26.81M 1.19B
Net income -4.34M -4.96M -4.01M -3.7M -7.02M -474M -7.15M -48.03M -18.69M -233M -18.6M -18.2M -806M -50.64M -57.83M -46.74M -43.18M -81.93M -5.53B -83.41M -560M -218M -2.71B -217M -212M -9.4B
Net Debt -132M -151M -122M -113M -214M -14.41B -217M -1.46B -568M -7.07B -566M -553M -24.5B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-